Nurix Therapeutics, Inc.
- Jurisdiction
United States - ISIN
US67080M1036 (NRIX )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
7
/ 7
Profile
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. Read full profile
Fundamentals
- Net revenue
€69.96M - Gross margin
36.2% - EBIT
-€184.35M - EBIT margin
-263.5% - Net income
-€166.76M - Net margin
-238.4%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| van Houte Hans | Chief Financial Officer |
|
|
|
|
| Hansen Gwenn | Chief Scientific Officer |
|
|
|
|
| Ring Christine | Chief Legal Officer |
|
|
|
|
| van Houte Hans | Chief Financial Officer |
|
|
|
|
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Cathie Wood |
|
|
|
Buy |
| Peter Brown |
|
|
|
Sell |